As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
Content to be used in accordance with local CPO guidelines
LuMIERE: A Phase 1/2 Study Evaluating Safety, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Patients With Advanced Solid Tumors
Jonathan McConathy*, Yusuf Menda, Jordi Rodon, Ajit H. Goenka, Ryan H. Moy, Sophie Morse, Arnaud Demange, Paola Aimone, Thomas A. Hope
Presentation #671P – Poster
Hall 6 | Saturday, September 14, 2024 | 09:00-17:00 CEST